hydrolase/inflammation

FIELD OF THE INVENTION This invention is in the field of antiinflammatory pharmaceutical agents and specifically relates to co-administration of an inhibitor of cyclooxygenase-2 and a leukotriene A.sub.4 hydrolase inhibitor for treating inflammation and inflammation-related disorders, such as

FIELD OF THE INVENTION This invention is in the field of antiinflammatory pharmaceutical agents and specifically relates to co-administration of an inhibitor of cyclooxygenase-2 and a leukotriene A.sub.4 hydrolase inhibitor for treating inflammation and inflammation-related disorders, such as

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention generally relates to methods of treating hypertension using inhibitors of epoxide hydrolases. Preferred inhibitors include compounds, such as ureas, amides, and carbamates that can interact with the enzyme catalytic site and

1. BACKGROUND 1.1 Technical Field The present invention relates to methods of design or identification of biologically active compounds which methods are based on the first definition ever of a three-dimensional structure of a protein involved in the leukotriene cascade. Further, the invention

BACKGROUND OF THE INVENTION Soluble epoxide hydrolase (sEH) is an enzyme involved in the conversion of epoxyeicosatrienoic acids (EETs) to dihydroxyeicosatrienoic acids (DHETs). Various studies have shown that EETs have anti-inflammatory properties, and so it has been suggested that inhibitors of

FIELD The present invention relates to the prevention, reduction, inhibition and reversal of pain and inflammation in a non-human mammal by administration of an inhibitor of soluble epoxide hydrolase, as sole active agent or co-administered with other active agents. BACKGROUND Laminitis is an

This application is a 371 of PCT/GB99/00284, filed Jan. 27, 1999. The present invention relates to the use of certain esters and thioesters for the treatment of diseases responsive to inhibition of intracellular leukotriene-A.sub.4 hydrolase activity. BACKGROUND TO THE INVENTION The leukotriene

FIELD OF THE INVENTION The present invention generally relates to methods of treating epoxide hydrolases so as to form complexes therewith, and more particularly relates to compounds, such as ureas, which complex with epoxide hydrolases and can be used to purify, isolate, or inhibit the epoxide

BACKGROUND OF THE INVENTION Leukotriene B.sub.4 (LTB.sub.4) is a potent pro-inflammatory activator of inflammatory cells, including neutrophils (J. Palmblad, J. Rheumatol. 1984, 13(2):163-172), eosinophils (A. M. Tager, et al., J. Exp. Med. 2000, 192(3):439-446), monocytes (N. Dugas et al., Immunol.

BACKGROUND OF THE INVENTION Leukotriene B.sub.4 (LTB.sub.4) is a potent pro-inflammatory activator of inflammatory cells, including neutrophils (J. Palmblad, J. Rheumatol. 1984, 13(2):163-172), eosinophils (A. M. Tager, et al., J. Exp. Med. 2000, 192(3):439-446), monocytes (N. Dugas et al., Immunol.

BACKGROUND OF THE INVENTION Leukotriene B.sub.4 (LTB.sub.4) is a potent pro-inflammatory activator of inflammatory cells, including neutrophils (J. Palmblad, J. Rheumatol. 1984, 13(2):163-172), eosinophils (A. M. Tager, et al., J. Exp. Med. 2000, 192(3):439-446), monocytes (N. Dugas et al., Immunol.

BACKGROUND OF THE INVENTION Leukotriene B.sub.4 (LTB.sub.4) is a potent pro-inflammatory activator of inflammatory cells, including neutrophils (J. Palmblad, J. Rheumatol. 1984, 13(2):163-172), eosinophils (A. M. Tager, et al., J. Exp. Med. 2000, 192(3):439-446), monocytes (N. Dugas et al., Immunol.

BACKGROUND OF THE INVENTION Leukotriene B.sub.4 (LTB.sub.4) is a potent pro-inflammatory activator of inflammatory cells, including neutrophils (J. Palmblad, J. Rheumatol. 1984, 13(2):163-172), eosinophils (A. M. Tager, et al., J. Exp. Med. 2000, 192(3):439-446), monocytes (N. Dugas et al., Immunol.

TECHNICAL FIELD This present disclosure describes compounds which include substituted amines and derivatives suitable as leukotriene A4 hydrolase inhibitors and useful in treating inflammatory disorders. BACKGROUND Leukotriene B.sub.4 (LTB.sub.4) is a potent pro-inflammatory activator of

BACKGROUND Inflammation is normally an acute response by the immune system to invasion by microbial pathogens, chemicals or physical injury. In some cases, however, the inflammatory response can progress to a chronic state and be the cause of inflammatory disease. Therapeutic control of this chronic